BACKGROUND:: Compared with the general population, individuals with schizophrenia
demonstrate an increased prevalence of obesity, type 2 diabetes mellitus (T2DM), and …

This study investigated whether illness progression and treatment refractoriness emerge
after relapse in schizophrenia. We compared outcomes in a cohort treated with a …

Background Whether or not second-generation antipsychotics (SGAs) represent an
advantage over first-generation antipsychotics (FGAs) in the treatment of schizophrenia is …

Background Although continuous treatment with antipsychotics is still recommended as the
gold standard treatment paradigm for all patients with schizophrenia, some clinicians …

Both conventional and atypical antipsychotics cause an up-regulation of dopamine-2
receptors and have been associated with tardive dyskinesia. Studies of adult and elderly …

Using a long-acting antipsychotic to improve adherence early in the illness may reduce
relapse rates and promote sustained remission, thereby improving the long-term outcome of …

Few studies have assessed the comparative efficacy and safety of atypical and typical
antipsychotic medications in patients within their first episode of psychosis. This study …

The aim of this review is to analyse and summarise the literature data about the incidence of
weight gain in patients exposed to atypical antipsychotics during long-term (≥ 1 year) …

Introduction Avoidance of relapse is the main aim of long-term antipsychotic treatment in
schizophrenia, yet how 'relapse'is defined in trials is not well-known. Methods We conducted …

Many patients with schizophrenia will relapse despite uninterrupted antipsychotic (AP) long-
acting therapy (LAT). This exploratory analysis examined variables associated with relapse …